Efficacy and safety of relugolix therapy for symptomatic uterine fibroids: a systematic review and meta-analysis
Authors:
- 11 December 2025
- journal article
- review article
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 318, 114889
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated PainDrugs, 2024
- Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension studyAmerican Journal of Obstetrics and Gynecology, 2023
- A Randomized Open-Label Study of Relugolix Alone or Relugolix Combination Therapy in Premenopausal WomenClinical Pharmacokinetics, 2023
- PRISMA2020 : An R package and Shiny app for producing PRISMA 2020‐compliant flow diagrams, with interactivity for optimised digital transparency and Open SynthesisCampbell Systematic Reviews, 2022
- Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroidsAmerican Journal of Obstetrics and Gynecology, 2020
- Preoperative medical therapy before surgery for uterine fibroidsCochrane Database of Systematic Reviews, 2017
- The relationship between uterine leiomyomata and pelvic floor symptomsInternational Urogynecology Journal, 2013
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Hormone treatment of endometriosis: The estrogenthreshold hypothesisAmerican Journal of Obstetrics and Gynecology, 1992
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986